Postoperative bleeding is still one of the most common complications of cardiac surgery.
INTRODUCTION
In time when systemic use of antifibrinolytic agents is highly controversial, with conflicting evidence of both benefits and adverse effects [1, 2, 3] , topical application of these agents in pericardial cavity could provide alternative means to effectively reduce postoperative bleeding.
Although the topical use of antifibrinolytic agents, such as aprotinin and tranexamic acid (TA), is not a novel method [4, 5] , it has not been widely accepted as a routine part of cardiac procedure.
One of the main reasons is lack of evidence to support regular topical use of antifibrinolytic agents [6] . Only one randomized controlled trial by De Bonnis [7] demonstrated a clinically small benefit in favor of topical TA application over placebo in a group of low risk coronary patients.
The aim of this study was to compare the effects of topically applied aprotinin with TA and placebo on postoperative bleeding and transfusion requirements. 
MATERIAL AND METHODS
After institutional approval was obtained, 300 patients scheduled for first-time elective cardiac procedure between May 2003 and April 2005 were enrolled in the study. The demographic data of our study groups is displayed in Table1. The study was carried out as a prospective, randomized, double-blind investigation with parallel groups.
Exclusion criteria were as follows: procedures of thoracic aorta, redo procedures, active endocarditis, emergent procedures and known preexisting coagulation defects or abnormal platelet count.
Pharmacological protocol
After the enrollment, patients were randomized into three groups using random-number tables.
The independent pharmacologist in hospital pharmacy prepared coded solutions with the study drugs or placebo and was not directly involved in the clinical treatment of randomized patients.
Solutions contained one million IU of aprotinin (Trasylol; Bayer Pharma d.o.o., Ljubljana, Slovenia) in 250 mL of saline solution (AP group), 2.5 g of TA (Cyklokapron; Pharmacia AB, Stockholm, Sweden) in 250 mL of saline solution (TA group) or 250 mL of saline as placebo (PL group), without any other additives or preservatives. Identical bottles marked with a study number of patient were delivered to the operating theaters. Both the operation theater staff and that of the intensive care unit were blinded regarding the study drug and codes were disclosed at the end of the study.
In all patients, antiaggregative therapy was discontinued for at least 5 days and anticoagulant therapy was continued up to 24 hours prior to surgery. There was no systemic appliance of either aprotinin or tranexamic acid in any patient.
Surgical procedures and drug administration
Different cardiac procedures were performed in this study ( Table 2) , reflecting the usual casemix performed at our Department. Patients with operations both with and without use of cardiopulmonary bypass (CPB) were included in study.
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After thorough surgical hemostasis and before closure of the median sternotomy, study solution at room temperature was poured into the pericardial cavity and over the mediastinal tissues. After chest closure, study solution was suctioned out through chest tubes. After the patient was transferred to the intensive care unit (ICU), continuous suction (20 cm H 2 O) was applied, which was supplemented with periodic milking of the drains.
Anesthetic protocol and cardiopulmonary bypass management
Same anesthetic protocols were used for all patients. All patients were premedicated with All cases which required CPB were performed in moderate hypothermia with cardiac arrest achieved with a single antegrade dose of blood cardioplegia followed by a continuous retrograde application of blood potassium cardioplegic solution.
Anticoagulation during operation
Heparin-sodium (Heparin; Belupo, Koprivnica, Croatia) was administered to achieve activated clotting time (ACT) of >480 seconds for patients undergoing the procedure with the use of CPB, and was checked every 20 minutes and re-administered according to the ACT values measured.
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For patients undergoing the procedure without CPB (off-pump), heparin was administered to achieve ACT time of at least 200 seconds.
In patients undergoing coronary revascularization (both on-and off-pump) heparin was administered at the end of LIMA takedown. In valvular patients heparin was administered upon placing the cannulation stitches.
At the end of the procedure heparin was fully reversed with protamine-hydrochloridum (Protamin ICN; ICN Pharmaceuticals, Birsfelden, Switzerland) in all patients. In patients undergoing surgery with the use of CPB heparin reversal started upon the removal of the venous cannula, and in patients undergoing off-pump surgery upon the completion of the last anastomosis.
Transfusion policy
Criteria for transfusion of packed red blood cells were as follows: hematocrit value less than 30% and haemoglobin value less than 90 g/dL accompanied by signs or symptoms of hypovolemia after CPB and during the ICU stay. The criterion for transfusion of fresh frozen plasma was a prothrombin time greater than 1.5 (international normalized ratio) with excessive bleeding, defined as greater than 200 mL/h for 2 consecutive hours. The criterion for transfusion of platelet concentrates was a platelet count less than 50,000/mm3 with excessive bleeding (>200 mL/h for 2 consecutive hours). Surgical re-exploration was performed if bleeding in the first 2 hours was greater than 300 mL/h or greater than 200 mL/h for 4 consecutive hours with normal coagulation parameters.
Data collection and laboratory analysis
Postoperatively, blood loss from the mediastinal chest tubes was recorded at 12 and 24 hours from the time patient arrived in the ICU. Blood product transfusions were documented for the entire postoperative hospital stay. All clinical data was harvested from CardioBase, custom-made database of cardiac patients that is routinely used at our Department.
Plasma concentration of hemoglobin, hematocrit level, platelet count, prothrombin time, activated partial thromboplastin time (aPTT) and fibrinogen levels were measured before operation and after patient's arrival in the ICU. 
RESULTS
Six patients were withdrawn from the study due to the postoperative reopening for bleeding where an evident surgical source of bleeding was discovered. One patient dropped-out from the study due to the technical mistake. A total of 293 patients were assessed in the study: 100 patients in AP group, 97 in TA group and 96 in PL group.
The three groups were comparable with regard to age, sex, diabetes and EuroSCORE (both additive and logistic), as shown in Table 1 . There were no inter-group differences concerning both CPB use (p=0.27) and percentage of isolated coronary surgery (p=0.29). Laboratory analyses showed not differences between the three groups, both pre- (Table ) and postoperatively (Table ) .
From 293 enrolled patients, 6 of them (2%) died: 2 in AP group, 1 in TA group, 3 in PL group (p=0.59). Three patients died of cardiac reasons (perioperative myocardial infarction -2, malignant arrhythmia -1) and 3 from non-cardiac reasons (sepsis -2, stroke -1).
Postoperative blood loss
Postoperative blood loss for first and second 12-hour periods, as well as cumulative blood loss at 24h is presented in Figure 1 (a-c) Figure 1 (d) 
Subgroups analyses
Statistical analysis of 2 subgroups of our study population has been performed. CPB subgroup included patients operated only with CPB support and OPCAB subgroup included patients operated without using CPB.
Results of CPB subgroup are displayed in Table . Again, significant inter-group differences were observed, concerning postoperative blood loss during first 12-hour period and cumulative blood loss within 24 hours. Posthoc analyses revealed that PL group differs significantly from both AP and TA groups, with no differences between later two. Decrease of mean cumulative blood loss at 24h was 37% (308 mL) in TA group, and 20% (163 mL) in AP group, when compared to placebo.
Results of OPCAB subgroup are displayed in Table . In this subgroup, inter-group difference was significant concerning only postoperative bleeding during first 12-hour period. Posthoc analyses revealed significant difference only between AP and PL group, with reduction of bleeding of 170ml (28%) in AP group.
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DISCUSSION
This study reveals favorable effect of topically applied antifibrinolytic agents after cardiac operation: both aprotinin and TA efficiently reduce blood loss in first 12 hours in a large and heterogeneous group of cardiac patients. Cumulative blood loss at 24h after surgery was significantly lower compared to placebo -by 20% in AP group and 30% in TA group. Although evident, the difference between two antifibrinolytic agents in favor of TA was not statistically significant. The fact that there is no difference between groups in blood loss during second 12-h period is anticipated and is in accordance with results from De Bonis and colleagues, who demonstrated that hemostatic effect of 1% solution of TA lasted for 3-4 hours [7] .
First study of topical application of antifibrinolytic agents was reported back in 1993, when Tatar and colleagues demonstrated evident reduction of both postoperative bleeding and the need for transfusion after topical use of aprotinin in 25 coronary patients [4] . Their results were further verified by double-blind, randomized trial on 100 patients undergoing cardiac operations with CPB published in 1995 by O'Regan and his group [5] . Cicek et al. [8] showed in 1995 that topically applied aprotinin could not be detected in blood and proposed that it locally relieves fibrinolytic state present in thoracic cavity after cardiopulmonary bypass. The same author year later raised a concern that aprotinin application in thoracic cavity may enhance postoperative mediastinal adhesion formation through its antifibrinolytic effects [9] De Bonis and colleagues [7] antifibrinolytic agents also failed to show differences in blood products transfusions [7, 10, 11, 12] .
Additional statistical analysis showed the same results in a subgroup of patients operated with use of CPB. On the other hand, in the subgroup of patients operated without use of CPB (OPCAB subgroup), significant difference was shown only concerning bleeding during first 12-hour periods, with only AP group being considerably lower then placebo! This result suggests that aprotinin is more potent then tranexamic acid when no CPB is being used. However, these results must be interpreted with caution, because of the smaller sample sizes of mentioned subgroups.
We also have to mention impressive differences regarding the cost of the 2 drugs: at our institution the aprotinin protocol costs round 71€ per patient, whereas the TA application costs only 23€ per patient.
Based on the results of this double blinded randomized trial, we can conclude that topical application of both aprotinin and TA efficiently reduces postoperative bleeding. TA seems to be at least as potent as aprotinin, but potentially safer and with better cost-effectiveness ratio. 
